Sifrol
PreclinicalSmall molecule
Boehringer IngelheimSifrol is one of 26 small molecule programs targeting Tremor. It is currently in Preclinical.
2
Indications
4
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Restless Legs Syndrome
#DrugCompanyPhaseTrials
1Neupro
UCBApproved
Mirapex
Boehringer IngelheimApproved
Requip Xl
GGlaxo Dba Glaxosmithkline
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Avelox
BayerApproved
Dostinex
PfizerApproved
Calciferol
Jazz PharmaceuticalsApproved
Injectafer
AAmerican Regent, Inc.
Approved
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Topamax
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tremor1 trial
Idiopathic Parkinson's Disease1 trial
Restless Legs Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sifrol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company